Rhinomed Limited is continuing to generate data that supports the Rhinoswab as the preferred sampling method for diagnosis of upper respiratory disease. The Rhinoswab is a novel sampling technology that radically improves the sample collection process. Rhinoswab makes sampling easy, comfortable and more acceptable and can be self administered. Existing studies have established that 8 out 10 people prefer the Rhinsowab over the traditional nasal swab. In addition, previously published data indicate that the Rhinoswab captures a statistically significant larger sample size than traditional nasal swabs. Rhinoswab works with existing pathology workflows and equipment, and is equivalent in cost with US and European swabs. A new trial at St Vincent's Hospital in Melbourne will seek to build on existing data that validates that the Rhinoswab as a superior method for sampling of upper respiratory diseases including SARS- CoV-2, RSV, Influenza A and B. The trial has two key objectives: Determine if users consider the Rhinoswab a more comfortable and convenient method for sample collection and, Compare the sensitivity, specificity and other measures of PCR test performance of the Rhinoswab compared to the traditional swab and saliva. The traditional nasal swab is the current gold standard in sampling for upper respiratory disease, despite the well established issues with patient reported pain and discomfort and the lack of consistency of application. These factors can significantly impact the specificity and sensitivity of a test result. Rhinomed has received Human Research Ethics Committee approval to commence the clinical trial at St Vincent's Hospital Melbourne. The trial will investigate: The laboratory test performance of the Rhinoswab compared with the current standard of care CTDN swab and saliva collection; The comfort and preference of Rhinoswab compared to the CTDN swab and saliva collection; If laboratory handling of Rhinoswab is equivalent to the CTDN swab and saliva collection.